knowledge -WSS

knowledge

author：fashion 2025-09-29 21:29:27 - browse：96

The back of three medicine containers, a bottle in between two boxes, all showing labels — coverage from STAT — Adobe

After a drug enters the market, it’s up to Food and Drug Administration regulators to ensure its continued safety and efficacy. A recent New York Times story suggests that, in the case of the popular asthma drug Singulair, the FDA fell short — both because the agency delayed action for years on reports from patient advocates and independent groups that the drug could cause suicidal thoughts, and because when it did add a warning label about its potential side effects in 2020, clinicians and patients still weren’t always aware of the risks.

Experts say that the Singulair incident highlights a flawed system, both in the U.S. and globally, for monitoring adverse reactions after a drug is on the market — one that will require extensive changes to address.

“The question is, how safe do you want to be?” said Ameet Sarpatwari, the assistant director of the Program on Regulation, Therapeutics, and Law at Brigham and Women’s Hospital. Ideally, he said, the FDA should be able to both stay on top of safety concerns and avoid unnecessarily restricting access to drugs. “Are we at the right balance? I think there are definitely situations for many drugs where you can say, no, we’re not really at the right balance, and the FDA should be taking a more aggressive stance in promoting patient safety.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical leaders decry Supreme Court decision on affirmative action
Next article： Dobbs anniversary: the lost opportunity of abortion as health care

focus

hotspot

WSS

Heart attack and stroke risk calculators need revising

Affirmative action in medical school literally saved lives

In age of alternative facts, a scholarly course on calling out crap

Cancer drug shortages should be causing more outrage

Sutter Health’s antitrust win overturned by appeals court

CMS got Medicare Advantage quality rating wrong, judge rules

knowledge

knowledge

explore

In age of alternative facts, a scholarly course on calling out crap

Fight over Supreme Court dialysis ruling puts kidney patients at risk

Peter Hotez and the public health issue of online harassment

STAT wants to know your pick for a great summer read or listen

Duchenne breakthrough therapy leaves behind pioneering families

Wildfire smoke exposes gaps in outdoor worker protections

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Data don't support strong claims for Covid

Guidelines to prevent youth baseball injuries need more muscle

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Wikipedia

New air purifier tech could be key to improving indoor air quality

Duchenne breakthrough therapy leaves behind pioneering families

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Elevance PBM president out as customers face prescription chaos

An outdated Medicare rule harms dementia patients with anxiety

Data don't support strong claims for Covid

leisure time

focus

hotspot

hotspot